News und Analysen

• Want Diversified Upside in Biotechnology? Check out LABU

Arrowhead Pharmaceuticals (NASDAQ:ARWR) is moving into a more commercial phase while continuing to expand its RNA interference pipeline

Orion Office REIT (NYSE:ONL) said its first-quarter results reflected continued progress on leasing, asset sales and balance-sheet management, while its board and management continue to evaluate

Rapid Micro Biosystems (NASDAQ:RPID) reported first-quarter 2026 revenue growth and reaffirmed its full-year outlook, citing momentum in system placements, consumables and recurring revenue, while

• Breakout Momentum Plays You Need to Know About

Omeros (NASDAQ:OMER) reported first-quarter 2026 net income of $56.1 million, or $0.78 per share, as the company began commercial sales of YARTEMLEA

• The 3 Penny Stocks You Swore You’d Never Buy (But You’ll Check Anyway)

Microvision (NASDAQ:MVIS) said its first-quarter results showed early commercial traction from its expanded lidar portfolio

Lightwave Logic (NASDAQ:LWLG) reported a wider first-quarter loss while outlining progress on customer engagement, foundry integration and commercialization efforts for its electro-optic polymer

• Before the Moon Base Gets Built, These 4 Companies Win

Aeluma (NASDAQ:ALMU) executives said the company is seeing increased customer interest in its photonics technology as artificial intelligence

• 3 Stocks With Sky-High Short Interest Levels

Allogene Therapeutics (NASDAQ:ALLO) said its first quarter of 2026 was marked by early clinical progress for its lead allogeneic CAR-T programs and a

ClearPoint Neuro (NASDAQ:CLPT) reported record first-quarter 2026 revenue and reaffirmed its full-year outlook, as management highlighted growth in its legacy neurosurgical device business and

• Alnylam Stock Soars 65%: Find Out What’s Behind the Gains

Alnylam Pharmaceuticals (NASDAQ:ALNY) Chief Financial Officer Jeff Poulton said the company remains confident in its TTR revenue guidance

• Novavax’s dispute resolution and upcoming earnings call

Valneva (NASDAQ:VALN) reported lower first-quarter revenue and a wider loss for 2026, while management said the company is focused on

Insiders are making moves in three stocks that have seen huge shifts in value over the recent past. This includes insiders buying shares in names that have fallen more than 30% and sales hitting

Innate Pharma (NASDAQ:IPHA) said its first-quarter 2026 business update centered on three priority clinical assets: lacutamab in cutaneous T-cell lymphoma, the Nectin-4 antibody-drug conjugate

• DarioHealth is an AI-Powered Digital Therapeutics Play

DarioHealth (NASDAQ:DRIO) reported sequential revenue growth for the second straight quarter while outlining plans to expand its digital

Merck KGaA (ETR:MRK) reported what executives described as a “solid start” to 2026, with organic growth in its Life Science and Electronics businesses offsetting a decline in Healthcare, and raised

• Cabot Boosting Production In Lithium Battery Chain For EV Market

Orion (NYSE:OEC) raised its full-year earnings outlook after reporting first-quarter adjusted EBITDA that exceeded internal

• 3 Bargain Stocks Under $20 With Major Growth Potential

NexGen Energy (NYSE:NXE) said its first quarter of 2026 marked a major transition point for the company, with Chief Executive Officer and

Envista (NYSE:NVST) reported a strong start to 2026, with management citing broad-based growth across its major dental businesses, margin expansion and continued investment in new products and

Astrana Health (NASDAQ:ASTH) CEO and President Brandon Sim said the value-based care company is seeing early benefits from its acquisition of Prospect, while reporting stronger-than-expected

TriSalus Life Sciences (NASDAQ:TLSI) reported slightly lower first-quarter revenue and reduced its full-year 2026 revenue outlook, citing disruption from a broad commercial reorganization and a